DE602005025750D1 - Verbindungen zur proteasomenzymhemmung - Google Patents
Verbindungen zur proteasomenzymhemmungInfo
- Publication number
- DE602005025750D1 DE602005025750D1 DE602005025750T DE602005025750T DE602005025750D1 DE 602005025750 D1 DE602005025750 D1 DE 602005025750D1 DE 602005025750 T DE602005025750 T DE 602005025750T DE 602005025750 T DE602005025750 T DE 602005025750T DE 602005025750 D1 DE602005025750 D1 DE 602005025750D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- compounds
- proteasome
- based compounds
- activities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56234004P | 2004-04-15 | 2004-04-15 | |
US56909604P | 2004-05-07 | 2004-05-07 | |
US59940104P | 2004-08-06 | 2004-08-06 | |
US61000204P | 2004-09-14 | 2004-09-14 | |
US61015904P | 2004-09-14 | 2004-09-14 | |
US61000104P | 2004-09-14 | 2004-09-14 | |
US62057304P | 2004-10-20 | 2004-10-20 | |
PCT/US2005/012740 WO2005105827A2 (en) | 2004-04-15 | 2005-04-14 | Compounds for proteasome enzyme inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005025750D1 true DE602005025750D1 (de) | 2011-02-17 |
Family
ID=34965899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005025750T Active DE602005025750D1 (de) | 2004-04-15 | 2005-04-14 | Verbindungen zur proteasomenzymhemmung |
Country Status (17)
Country | Link |
---|---|
US (9) | US8129346B2 (de) |
EP (1) | EP1745064B1 (de) |
JP (3) | JP5616569B2 (de) |
CN (2) | CN103554222A (de) |
AT (1) | ATE494298T1 (de) |
AU (1) | AU2005238445B2 (de) |
BR (1) | BRPI0509879A (de) |
CA (1) | CA2562411A1 (de) |
CY (1) | CY1117244T1 (de) |
DE (1) | DE602005025750D1 (de) |
DK (1) | DK1745064T3 (de) |
HK (1) | HK1097860A1 (de) |
IL (3) | IL178400A (de) |
PL (1) | PL1745064T3 (de) |
PT (1) | PT1745064E (de) |
SG (2) | SG185306A1 (de) |
WO (1) | WO2005105827A2 (de) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105827A2 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
AU2012203602B2 (en) * | 2004-04-15 | 2015-08-27 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
BRPI0510802A (pt) | 2004-05-10 | 2007-11-06 | Proteolix Inc | compostos para inibição de enzima |
PL2260835T3 (pl) | 2004-12-07 | 2013-08-30 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス, インク. | 酵素阻害のための化合物 |
US7691852B2 (en) | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
MY173938A (en) | 2007-10-04 | 2020-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
KR20110073584A (ko) | 2008-10-21 | 2011-06-29 | 오닉스 세라퓨틱스, 인크. | 펩티드 에폭시케톤과의 병용 요법 |
CA2756804C (en) | 2009-03-16 | 2020-12-22 | The Governing Council Of The University Of Toronto | Cyclic amino acid molecules and methods of preparing the same |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
GB0914883D0 (en) | 2009-08-26 | 2009-09-30 | Univ Belfast | Compound |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
EP2542238B1 (de) | 2010-03-01 | 2015-08-12 | Onyx Therapeutics, Inc. | Verbindungen zur immunproteasomhemmung |
MX2012011604A (es) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
US10159746B2 (en) | 2012-05-08 | 2018-12-25 | Onyx Therapeutics, Inc. | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |
EP2869820A4 (de) | 2012-07-09 | 2016-02-17 | Onyx Therapeutics Inc | Prodrugs von peptidepoxidketonproteaseinhibitoren |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
SG10201913777XA (en) | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
MX2016000568A (es) | 2013-07-19 | 2016-08-01 | Onyx Therapeutics Inc | Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres. |
CN103360348B (zh) * | 2013-07-25 | 2015-06-24 | 苏州鹏旭医药科技有限公司 | 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法 |
CA2920220A1 (en) * | 2013-09-06 | 2015-03-12 | Sandoz Ag | Synthesis of peptide epoxy ketones |
WO2015032622A1 (en) * | 2013-09-06 | 2015-03-12 | Sandoz Ag | Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib |
CN104710507B (zh) * | 2013-12-11 | 2018-08-14 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
WO2015121769A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate |
US10640533B2 (en) | 2014-07-14 | 2020-05-05 | Centrax International, Inc. | Epoxyketone compounds for enzyme inhibition |
US10329325B2 (en) | 2014-09-24 | 2019-06-25 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
CN107548400A (zh) | 2014-12-02 | 2018-01-05 | 费森尤斯卡比肿瘤学有限公司 | 卡非佐米的纯化方法 |
US10301353B2 (en) | 2014-12-31 | 2019-05-28 | Dr. Reddy's Laboratories Limited | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib |
WO2016116882A2 (en) * | 2015-01-23 | 2016-07-28 | Leiutis Pharmaceuticals Pvt Ltd | Novel compositions of carfilzomib |
WO2016170544A1 (en) * | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide |
WO2016170489A1 (en) | 2015-04-24 | 2016-10-27 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of proteasome inhibitor |
WO2016185450A1 (en) | 2015-05-21 | 2016-11-24 | Laurus Labs Private Limited | An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof |
US11072616B2 (en) | 2015-11-11 | 2021-07-27 | Universite De Montreal | Cyclic peptides targeting alpha-4-beta-7 integrin |
EP3494126A1 (de) | 2016-08-02 | 2019-06-12 | Synthon BV | Verfahren zur herstellung von carfilzomib |
US11078231B2 (en) | 2016-09-14 | 2021-08-03 | Fresenius Kabi Oncology Ltd | Process for purification of carfilzomib intermediate |
WO2018085921A1 (en) | 2016-11-11 | 2018-05-17 | Encycle Therapeutics, Inc. | CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN |
EP3330260A1 (de) | 2016-12-01 | 2018-06-06 | Enantia, S.L. | Verfahren zur herstellung eines zwischenprodukts zur synthese von i. a. carfilzomib |
CN106946981B (zh) * | 2017-03-08 | 2020-08-21 | 南京陵瑞医药科技有限公司 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
JP7274425B2 (ja) | 2017-05-10 | 2023-05-16 | ジーランド ファーマ アクティーゼルスカブ | α4β7インテグリンを標的とするホモデチック環状ペプチド |
WO2019053611A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
CN113185575B (zh) * | 2021-05-11 | 2022-07-12 | 四川大学 | 一种花生抗氧化多肽及其制备方法 |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
JPH01136498A (ja) | 1987-11-21 | 1989-05-29 | Nec Corp | 状態監視用情報伝送装置 |
US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5071957A (en) * | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
AU661270B2 (en) | 1990-03-05 | 1995-07-20 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
GB9300048D0 (en) * | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
IL129407A0 (en) * | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
CA2274789A1 (en) | 1996-12-13 | 1998-06-18 | Zymogenetics, Inc. | Compositions and methods for stimulating bone growth |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
EP0986403B1 (de) * | 1997-06-13 | 2003-11-12 | Cydex Inc. | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden |
US6099851A (en) * | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
EP1123412B1 (de) * | 1998-10-20 | 2004-10-06 | Millennium Pharmaceuticals, Inc. | Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
EP1221962A2 (de) | 1999-10-20 | 2002-07-17 | Osteoscreen, Inc. | Hemmstoffe der proteasom aktivität zur stimulierung von knochen- und haarwachstum |
EP1430903A1 (de) * | 2000-10-12 | 2004-06-23 | Viromics Gmbh | Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen |
US7524883B2 (en) * | 2002-01-08 | 2009-04-28 | Eisai R&D Management Co., Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
WO2003086283A2 (en) * | 2002-04-09 | 2003-10-23 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US20030224469A1 (en) * | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
WO2005105827A2 (en) * | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for proteasome enzyme inhibition |
US20050256324A1 (en) * | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
BRPI0510802A (pt) | 2004-05-10 | 2007-11-06 | Proteolix Inc | compostos para inibição de enzima |
WO2006045066A2 (en) * | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
PL2260835T3 (pl) * | 2004-12-07 | 2013-08-30 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
WO2006099261A2 (en) | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス, インク. | 酵素阻害のための化合物 |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
DE102006026464A1 (de) * | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
US7691852B2 (en) * | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
JP4325683B2 (ja) * | 2007-02-14 | 2009-09-02 | セイコーエプソン株式会社 | 画像表示装置、及び画像表示装置の制御方法 |
WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
MY173938A (en) | 2007-10-04 | 2020-02-27 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
KR20110073584A (ko) | 2008-10-21 | 2011-06-29 | 오닉스 세라퓨틱스, 인크. | 펩티드 에폭시케톤과의 병용 요법 |
-
2005
- 2005-04-14 WO PCT/US2005/012740 patent/WO2005105827A2/en active Application Filing
- 2005-04-14 CA CA002562411A patent/CA2562411A1/en not_active Abandoned
- 2005-04-14 AU AU2005238445A patent/AU2005238445B2/en active Active
- 2005-04-14 SG SG2012076659A patent/SG185306A1/en unknown
- 2005-04-14 JP JP2007508543A patent/JP5616569B2/ja active Active
- 2005-04-14 CN CN201310512372.8A patent/CN103554222A/zh active Pending
- 2005-04-14 DE DE602005025750T patent/DE602005025750D1/de active Active
- 2005-04-14 US US11/578,626 patent/US8129346B2/en active Active
- 2005-04-14 EP EP05735686A patent/EP1745064B1/de active Active
- 2005-04-14 SG SG200902548-7A patent/SG152239A1/en unknown
- 2005-04-14 DK DK05735686.7T patent/DK1745064T3/da active
- 2005-04-14 PL PL05735686T patent/PL1745064T3/pl unknown
- 2005-04-14 AT AT05735686T patent/ATE494298T1/de active
- 2005-04-14 CN CN201110037869XA patent/CN102174076A/zh active Pending
- 2005-04-14 PT PT05735686T patent/PT1745064E/pt unknown
- 2005-04-14 BR BRPI0509879-3A patent/BRPI0509879A/pt not_active Application Discontinuation
-
2006
- 2006-09-28 IL IL178400A patent/IL178400A/en active IP Right Grant
-
2007
- 2007-05-14 HK HK07105045.7A patent/HK1097860A1/xx unknown
-
2011
- 2011-02-18 CY CY20111100205T patent/CY1117244T1/el unknown
- 2011-09-12 JP JP2011198810A patent/JP2012041346A/ja active Pending
- 2011-12-22 US US13/334,288 patent/US8207125B2/en active Active
- 2011-12-22 US US13/334,263 patent/US8207124B2/en active Active
- 2011-12-22 US US13/334,466 patent/US8207126B2/en active Active
- 2011-12-22 US US13/334,469 patent/US8207297B2/en active Active
- 2011-12-22 US US13/334,372 patent/US8324174B2/en active Active
- 2011-12-22 US US13/334,544 patent/US8207127B2/en active Active
- 2011-12-26 IL IL217211A patent/IL217211A0/en unknown
- 2011-12-26 IL IL217210A patent/IL217210A0/en unknown
-
2012
- 2012-03-02 US US13/411,044 patent/US20120277146A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/797,740 patent/US20130324459A1/en not_active Abandoned
- 2013-08-05 JP JP2013162017A patent/JP2014012676A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005025750D1 (de) | Verbindungen zur proteasomenzymhemmung | |
DE602005026019D1 (de) | Verbindungen zur proteasomenzymhemmung | |
EP2564834A3 (de) | Verbindungen zur Proteasomenzyminhibition | |
MY145757A (en) | Compounds for enzyme inhibition | |
WO2008140782A3 (en) | Compounds for enzyme inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R097 | No opposition filed against granted patent, or epo opposition proceedings concluded without decision |
Ref document number: 1745064 Country of ref document: EP Effective date: 20111006 |
|
R081 | Change of applicant/patentee |
Ref document number: 1745064 Country of ref document: EP Owner name: PROTEOLIX, INC., US Free format text: FORMER OWNER: PROTEOLIX, INC., SOUTH SAN FRANCISCO, US Effective date: 20120216 |
|
R082 | Change of representative |
Ref document number: 1745064 Country of ref document: EP |
|
R082 | Change of representative |
Ref document number: 1745064 Country of ref document: EP |